Skip to content

Coeptis Therapeutics, Inc.

CIK 0001819663

← back to feed
Revenue (TTM)
$0
+143.8% YoY Q3 Nov 2022
Net Income (TTM)
−$40.58M
−2,231.0% YoY Q3 Nov 2022
EPS Diluted (TTM)
—
Q3 Nov 2022
Gross Margin
—
Q3 Nov 2022
Operating Margin
—
Q3 Nov 2022
Net Margin
—
Q3 Nov 2022
Free Cash Flow (TTM)
−$4.49M
Q3 Nov 2022
Cash
$6.36K
Q3 Nov 2022
Total Debt
$150K
Q3 Nov 2022
Shares Outstanding
19.52M sh
Q3 Nov 2022

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings